E70.29
Other disorders of tyrosine metabolism
Clinical Classification Guidelines
Inclusion Terms
- Alkaptonuria
- Ochronosis
Medical Intelligence & Overview
Other disorders of tyrosine metabolism, classified under ICD-10 code E70.29, include rare inherited conditions that affect how the body processes the amino acid tyrosine. One notable example is alkaptonuria, a hereditary disorder where a deficiency of certain enzymes leads to the accumulation of homogentisic acid, causing symptoms like darkening of urine and tissue discoloration. These metabolic disorders can have progressive health effects, impacting various tissues and organs over time. Due to their rarity and complexity, understanding the core aspects of these conditions is crucial for accurate diagnosis and management.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting enzymes involved in tyrosine degradation, such as homogentisate 1,2-dioxygenase in alkaptonuria. Inheritance typically follows an autosomal recessive pattern, meaning both parents must pass on the mutated gene for the disorder to manifest. Enzymatic deficiency leads to buildup of metabolic intermediates that cannot be properly processed and eliminated by the body.
Key Symptoms: Dark coloration of urine that becomes evident when exposed to air, especially in early childhood. Progressive pigmentation of connective tissues, a condition known as ochronosis, giving tissues a bluish-black hue. Joint pain and stiffness due to the deposition of pigment in cartilage, leading to early-onset osteoarthritis. Discoloration of skin, sclerae, and ear cartilage in more advanced cases. Potential cardiovascular issues as pigment deposits affect heart valves and vessels. Other signs may include fatigue, reduced mobility, and in some cases, joint deformities.
Diagnostic & Treatment
Diagnosis Path: Diagnosis typically involves a combination of clinical assessment and laboratory investigations, including: - Urinalysis: detection of dark-colored urine, especially after air exposure. - Quantitative measurement of homogentisic acid in urine. - Genetic testing to identify mutations in relevant genes. - Imaging studies for evaluation of joint and tissue involvement. - Biopsy of affected tissues may reveal tissue pigmentation consistent with ochronosis. - Family medical history assessment, given hereditary nature.
Treatment Protocols: Currently, there are no universal cures for these metabolic disorders; management focuses on symptom control and slowing disease progression: - Regular monitoring to assess joint health and organ function. - Physical therapy and exercise to maintain mobility and strength. - Pain management strategies, including medications or alternative therapies. - Dietary modifications to reduce intake of tyrosine and phenylalanine, although evidence of effectiveness varies. - In some cases, antioxidants and medications like nitisinone have shown promise in reducing homogentisic acid levels. - Surgical interventions may be necessary for joint deformities or cardiovascular complications. - Supportive care and counseling for patients and families about disease progression.
Clinical Advice & FAQs
Billing Guidance
Is E70.29 a billable ICD-10 code?
Yes, E70.29 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E70.29?
Clinical documentation must specify the nature of Other disorders of tyrosine metabolism and any associated comorbidities for accurate reporting.
Cite this Clinical Reference